Measuring treatment impact: A review of patient-reported outcomes and other efficacy endpoints in approved product labels

Controlled Clinical Trials

Volumn 25, Issue 6, 2004, Pages 535-552

  Willke, Richard J ^a   Burke, Laurie B ^b   Erickson, Pennifer ^c  

^a PFIZER INC   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Drug development; Drug labeling; Health related quality of life; Patient reported outcomes

Indexed keywords

ALMOTRIPTAN; ALOSETRON; ANESTHETIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIDOTE; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMIGRAINE AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; ANTIVIRUS AGENT; BEHENYL ALCOHOL; BROMFENAC; CARDIOVASCULAR AGENT; CELECOXIB; CENTRAL NERVOUS SYSTEM AGENTS; CEVIMELINE; DERMATOLOGICAL AGENT; ELETRIPTAN; EMEDASTINE; ETIRACETAM; FROVATRIPTAN; GASTROINTESTINAL AGENT; HEMATOLOGIC AGENT; HORMONE; HYPOCHOLESTEROLEMIC AGENT; IMMUNOLOGIC AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; KETOTIFEN FUMARATE; LEXIDRONAM SAMARIUM SM 153; NARATRIPTAN; NEUROLEPTIC AGENT; OSELTAMIVIR; OXCARBAZEPINE; OXYBATE SODIUM; PEMIROLAST; RIZATRIPTAN; SEX HORMONE; SILDENAFIL; SUCRAID; TIAGABINE; TOLTERODINE; TROGLITAZONE; UNINDEXED DRUG; VACCINE; ZANAMIVIR; ZOLMITRIPTAN; ZONISAMIDE;

BONE CANCER; CANCER PAIN; CATAPLEXY; CLINICAL TRIAL; COMPARATIVE STUDY; DEVICE; DIARRHEA; DRUG EFFICACY; DRUG INDUSTRY; DRUG LABELING; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; INCONTINENCE; INFLUENZA; LABORATORY TEST; MICTURITION; MIGRAINE; OCULAR PRURITUS; OUTCOMES RESEARCH; PATIENT SATISFACTION; PRACTICE GUIDELINE; REVIEW; SEIZURE; XEROSTOMIA;

CLINICAL TRIALS; DRUG LABELING; DRUG THERAPY; ENDPOINT DETERMINATION; HEALTH STATUS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 9944234591     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2004.09.003     Document Type: Review

References (53)

1. Robert H. Brook, John E. Ware Jr., William H. Rodgers, Emmett B. Keeler, Allyson R. Davies, and Cathy A. Donald Does free care improve adults' health? Results from a randomized controlled trial N. Engl. J. Med. 309 23 1983 1426 1434
2. R.H. Brook, J.E. Ware Jr., A. Davies-Avery, A.L. Stewart, C.A. Donald, and W.H. Rogers Overview of adult health status measures fielded in Rand's Health Insurance Study Med. Care 17 7 Suppl. 1979 1 131
3. A.R. Tarlov, J.E. Ware Jr., S. Greenfield, E.C. Nelson, E. Perrin, and M. Zubkoff The Medical Outcomes Study: an application of methods for monitoring the results of medical care J. Am. Med. Assoc. 262 7 1989 925 930
4. P.M. Ellwood Shattuck Lecture-Outcomes management: a technology of patient experience N. Engl. J. Med. 318 23 1988 1549 1556
5. J.R. Johnson, and R. Temple Food and Drug Administration requirements for approval of new anticancer drugs Cancer Treat. Rep. 69 10 1985 1155 1157
6. S.H. Croog, S. Levine, M.A. Testa, B. Brown, C.J. Bulpitt, and C.D. Jenkins The effects of antihypertensive therapy on the quality of life N. Engl. J. Med. 314 26 1986 1657 1664
7. J. Bishop Squibb drug called superior in easing high blood pressure: findings of medical journal are leaked, prompting a jump in price of stock Wall Street Journal 1986 (6/25)
8. L. Burke Acceptable evidence for pharmaceutical advertising and labeling DIA Workshop on Pharmacoeconomic and Quality of Life Labeling and Marketing Claims 2000 (October 3) [presentation]
9. D. Revicki Consistent patient-reported outcomes Value Health 5 4 2002 295 296 [editorial]
10. D.A. Revicki, D. Osoba, D. Fairclough, I. Barofsky, R. Berzon, N.K. Leidy, and M. Rothman Recommendations on health-related quality of life research to support labeling and promotional claims in the United States Qual. Life Res. 9 2000 887 900
11. D.L. Patrick, and P. Erickson Health status and health policy: quality of life in health care evaluation and resource allocation 1993 Oxford University Press New York
12. C. Acquadro, R. Berzon, D. Dubois, N.K. Leidy, P. Marquis, D. Revicki for the PRO Harmonization Group Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001 Value Health 6 5 2003 522 531
13. Hippocrates. The Book of Prognostics, Part 2 (approx. 400 B.C.). As translated by Francis Adams (Great Books Index, 1977-99). http://classics.mit. edu/Hippocrates/prognost.html.
14. Joint Cmte on Stds for Educational and Psychological Testing of the American Educational Research Assn, the Am Psychological Assn, and the Nat'l Council on Measurement in Education Standards for educational and psychological testing 1999 American Educational Research Assn Wash. (DC)
15. Task Force on Pain Management Practice guidelines for chronic pain management Anesthesiology 86 1997 995 1004
16. R. Ferrini, and S.H. Woolf Screening for prostate cancer in American men: American College of Preventive Medicine Practice Policy Statement Am. J. Prev. Med. 15 1 1998 (Jul.) 81 84
17. Renal Physicians Association Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis J. Am. Soc. Nephrol. 11 7 2000 (Jul) 1340 1342
18. A. Garratt, L. Schmidt, A. Mackintosh, and R. Fitzpatrick Quality of life measurement: bibliographic study of patient assessed health outcome measures BMJ 324 2002 1417
19. S.N. Shah, A.M. Sesti, K. Copley-Merriman, and M. Plante Quality of life terminology included in package inserts for U.S. approved medications Qual. Life Res. 12 2003 1107 1117
20. Apolone G., De Carli G., Brunetti M., Garattini S. Health-related quality of life (HR-QOL) and regulatory issues: an assessment of European Agency for the Evaluation of Medicinal Products (EMEA) recommendation on the use of HR-QOL measures in drug approval.
21. B. Crawford, and L.B. Burke Meeting the US FDA's evidence standard with health-related quality of life claims Expert Rev. Pharmacoecon. Outcomes Res. 2 5 2002 401 402
22. I.B. Wilson, and P.D. Cleary Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes JAMA 273 1 1995 59 65
23. T.M. Gill, and A.R. Feinstein A critical appraisal of the quality of quality-of-life measurements JAMA 272 8 1994 619 626
24. Center for Drug Evaluation and Research. New Drug Approval Reports. U.S. Food and Drug Administration 2002. http://www.fda.fob/cder/rdmt/. Accessed Jan-Mar, 2002.
25. Center for Biologics Evaluation and Research. Approvals by year since 1996. U.S. Food and Drug Administration 2002. http://www.fda.gov/cber/products. htm. Accessed Jan-Mar, 2002.
26. Physicians desk reference 2002 Medical Economics Montvale (NJ)
27. P. Erickson, and J. Scott The On-Line Guide to Quality-of-Life Assessment (OLGA): resource for selecting quality-of-life assessments S.R. Walker R.M. Rosser Quality of life assessment: key issues in the 1990s 1993 Kluwer Academic Publishers Dordrecht, The Netherlands 221 232
28. Raymond C. Rosen, Alan Riley, Gorm Wagner, Ian H. Osterloh, John Kirkpatrick, and Avanish Mishra The International Index of Erectile Dysfunction (IIEF): a multidimensional scale for assessment of erectile dysfunction Urology 49 6 1997 822 830
29. Theodore Pincus, Jane A. Summey, Salvatore A. Soraci Jr., Kenneth A. Wallston, and Norman P. Hummon Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire Arthritis Rheum. 26 11 1983 1346 1353
30. James F. Fries, Patricia W. Spitz, Kraines R. Guy, and Halsted R. Holman Measurement of patient outcome in arthritis Arthritis Rheum. 23 2 1980 137 145
31. Nicholas Bellamy, W. Watson Buchanan, Charles H. Goldsmith, J. Campbell, and L.W. Stitt Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J. Rheumatol. 15 12 1988 1833 1840
32. Michael J. Barry, Floyd J. Fowler Jr., Michael P. O'Leary, R.C. Bruskewitz, H.L. Holtgrewe, and W.K. Mebust The American Urological Association symptom index for benign prostatic hyperplasia J. Urol. 148 1992 (Nov) 1549 1557
33. John E. Ware Jr., and Cathy Donald Sherbourne The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection Med. Care 30 6 1992 473 483
34. A.Y. Finlay Quality of life assessments in dermatology Semin. Cutan. Med. Surg. 17 4 1998 291 296
35. M. Bergner, R.A. Bobbitt, W.B. Carter, and B.S. Gilson The sickness impact profile: development and final revision of a health status measure Med. Care 19 8 1981 707 805
36. G. Regensteiner, F. Steiner, and J. Panzer Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease J. Vasc. Med. Biol. 2 3 1990 142 152
37. M. Morgan, R. McCreedy, J. Simpson, and R.J. Hay Dermatology quality of life scales: a measure of the impact of skin diseases Br. J. Dermatol. 136 2 1997 202 206
38. A.Y. Finlay Quality of life assessments in dermatology Semin. Cutan. Med. Surg. 17 4 1998 291 296
39. R.R. Rubin, and M. Peyrot Quality of life and diabetes Diabetes/Metab. Res. Rev. 15 3 1999 205 218
40. A. Hirsch, C. Bartholomae, and T. Volmer Dimensions of quality of life in people with non-insulin-dependent diabetes Qual. Life Res. 9 2 2000 207 218
41. J.A. Sloan, D. Cella, M. Frost, G.H. Guyatt, M. Sprangers, and T. Symonds Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms Mayo Clin. Proc. 77 4 2002 367 370
42. E.F. Juniper, G.H. Guyatt, A. Willan, and L.E. Griffith Determining a minimal important change in a disease-specific quality of life questionnaire J. Clin. Epidemiol. 47 1994 81 87
43. G. Samsa, D. Edelman, M.L. Rothman, G.R. Williams, J. Lipscomb, and D. Matchar Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II Pharmacoeconomics 15 2 1999 141 156
44. R.D. Hays, and J.M. Woolley The concept of clinically meaningful difference in health-related quality of life: how meaningful is it? Pharmacoeconomics 18 5 2000 419 423
45. Lipscomb J, Gotay CC, Snyder S, editors. Outcomes Assessment in Cancer. Cambridge University Press (in press).
46. G.R. Parkerson Jr., W.E. Broadhead, and C.K.J. Tse Health status and severity of illness as predictors of outcomes in primary care Med. Care 33 1 1995 53 66
47. L.M. Osman, D.J. Godden, J.G. Douglas, J.A.R. Friend, and J.S. Legge Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease Thorax 52 1997 67 71
48. C.E. Lee, M.J. Simmonds, D.M. Novy, and S. Jones Self-reports and clinician-measured physical function among patients with low back pain: a comparison Arch. Phys. Med. Rehabil. 82 2 2001 227 231
49. J.A. Cramer, C. Arrigo, and G. Van Hammee The effect of levetiracetam on epilepsy-related quality of life Epilepsia 41 2000 868 874
50. N.C. Santanello, A.B. Polis, S.L. Hartmaier, M.S. Kramer, G.A. Block, and S.D. Silberstein Improvement in migraine-specific quality of life in a clinical trial of rizatriptan Cephalgia 17 1997 867 872
51. A.A. Stone, S. Shiffman, J.E. Schwartz, J.E. Broderick, and M.R. Hufford Patient non-compliance with paper diaries BMJ 324 2002 1993 1994
52. Murray W. Johns A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale Sleep 14 6 1991 540 545
53. Gordon Guyatt, Alba Mitchell, E. Jan Irvine, J. Singer, N. Williams, and R. Goodacre A new measure of health status for clinical trials in inflammatory bowel disease Gastroenterology 96 3 1989 804 810